Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.68 |
| ▸ | SLC5A1 | P13866 | 12/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27084747 | 0.93 | SLC5A2 (0.69) | SLC5A2SLC5A1 | |
| SCHEMBL27085097 | 0.91 | SLC5A2 (0.69) | SLC5A2SLC5A1 | |
| SCHEMBL26790211 | 0.91 | SLC5A2 (0.70) | SLC5A2SLC5A1 | |
| SCHEMBL30882768 | 0.91 | SLC5A2 (0.70) | SLC5A2SLC5A1 | |
| SCHEMBL26792799 | 0.91 | SLC5A2 (0.70) | SLC5A2SLC5A1 | |
| SCHEMBL27085163 | 0.91 | SLC5A2 (0.70) | SLC5A2SLC5A1 | |
| SCHEMBL26790147 | 0.91 | SLC5A2 (0.70) | SLC5A2SLC5A1 | |
| SCHEMBL27085009 | 0.89 | SLC5A2 (0.54) | SLC5A2SLC5A1 | |
| SCHEMBL27084845 | 0.89 | SLC5A2 (0.63) | SLC5A2SLC5A1 | |
| SCHEMBL26795763 | 0.89 | SLC5A2 (0.68) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024042239-A1 | GLYCOSYLATED PSILOCIN DERIVATIVES AND METHODS OF USE | CY BIOPHARMA AG (CH) | 2024-02-29 | — | — | WO | disclosed |
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | COMPASS PATHFINDER LIMITED (GB) | 2024-02-08 | — | — | US | disclosed |
| CN-117120415-A | Modified indole alkaloids for therapeutic use | 指南针探路者有限公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023217800-A2 | GLYCOSYLATED COMPOSITIONS AND METHODS OF USE | CY BIOPHARMA AG (CH) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | INMT, AANAT, HNMT | SLC5A2 3921/4885SLC5A1 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.